Guardant Health Secures European Approval for Breast Cancer Companion Diagnostic
Event summary
- Guardant360® CDx received CE-marking in Europe as a companion diagnostic for AstraZeneca’s ETCAMAH™ in advanced ER-positive breast cancer.
- This is the third CDx approval for ETCAMAH and the 31st for Guardant Health.
- Guardant360 CDx detects ESR1 mutations via liquid biopsy, enabling earlier treatment decisions.
- Prior approvals for Guardant360 CDx as a companion diagnostic for ETCAMAH were secured in the U.S. and Japan.
The big picture
This approval solidifies Guardant Health’s role in precision oncology, particularly in enabling earlier intervention through liquid biopsy. The strategic partnership with AstraZeneca underscores the growing reliance on companion diagnostics to personalize cancer treatment. With 31 CDx approvals, Guardant Health is positioning itself as a key player in the shift toward data-driven oncology care.
What we're watching
- Market Expansion
- How Guardant Health will leverage this approval to expand its presence in Europe’s healthcare market.
- Clinical Utility
- Whether the liquid biopsy approach will become standard for early treatment decisions in other cancer types.
- Regulatory Momentum
- The pace at which Guardant Health can secure additional companion diagnostic approvals globally.
Related topics
